ASTELLAS PHARMA EUROPE B.V.

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ASP1128
Drug: Placebo

First Posted Date: 2021-02-08

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 102

Registration Number: NCT04742517

Locations: 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

A Study of ASP8302 in Participants With Underactive Bladder

Phase 2

Completed

Conditions: Underactive Bladder

Interventions: Drug: ASP8302
Drug: Placebo

First Posted Date: 2018-10-11

Last Posted Date: 2024-11-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 135

Registration Number: NCT03702777

Locations: 🇯🇵
Site JP81001, Shimotsuga-gun, Tochigi, Japan
🇯🇵
Site JP81004, Kumamoto, Japan
🇯🇵
Site JP81010, Saga, Japan

and more 26 locations

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

Phase 2

Completed

Conditions: Bladder Pain Syndrome
Interstitial Cystitis

Interventions: Drug: ASP6294
Drug: Placebo

First Posted Date: 2017-09-13

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 119

Registration Number: NCT03282318

Locations: 🇭🇺
Site HU36002, Budapest, Hungary
🇭🇺
Site HU36001, Csongrad, Hungary
🇨🇿
Site CZ42002, Plzen, Czechia

and more 25 locations

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ASP7713

First Posted Date: 2017-04-11

Last Posted Date: 2018-03-07

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 40

Registration Number: NCT03108755

Locations: 🇬🇧
Site GB44001, Harrow, Middlesex, United Kingdom

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Phase 1

Completed

Conditions: Normal Renal Function
Impaired Renal Function

Interventions: Drug: Roxadustat

First Posted Date: 2016-11-16

Last Posted Date: 2020-02-12

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 34

Registration Number: NCT02965040

Locations: 🇩🇪
Site DE49001, Munchen, Germany
🇬🇧
Site GB44001, Liverpool, United Kingdom

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Ipragliflozin L-proline
Drug: Metformin
Drug: Placebo

First Posted Date: 2016-06-09

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 268

Registration Number: NCT02794792

Locations: 🇷🇺
Site RU70005, Moscow, Russian Federation
🇷🇺
Site RU70003, Moscow, Russian Federation
🇷🇺
Site RU70011, Moscow, Russian Federation

and more 11 locations

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy

Phase 4

Terminated

Conditions: NSAID-induced Gastropathy

Interventions: Drug: bismuth tripotassium dicitrate
Drug: pantoprazole

First Posted Date: 2016-06-02

Last Posted Date: 2017-09-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 9

Registration Number: NCT02788123

Locations: 🇷🇺
Site RU70008, Saint-Petersburg, Russian Federation
🇷🇺
Site RU70012, Saint-Petersburg, Russian Federation
🇷🇺
Site RU70013, Volgograd, Russian Federation

and more 2 locations

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Phase 3

Completed

Conditions: Neurogenic Detrusor Overactivity

Interventions: Drug: Mirabegron

First Posted Date: 2016-04-26

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 91

Registration Number: NCT02751931

Locations: 🇷🇴
Site RO40001, Bucuresti, Romania
🇸🇰
Site SK42101, Bratislava, Slovakia
🇯🇴
Site JO96202, Amman, Jordan

and more 29 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Pharmacokinetics of ASP6294

Interventions: Drug: ASP6294 Intravenous
Drug: ASP6294 Subcutaneous
Drug: Placebo Intravenous
Drug: Placebo Subcutaneous

First Posted Date: 2016-02-15

Last Posted Date: 2017-01-10

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 74

Registration Number: NCT02681861

Locations: 🇬🇧
Site GB44001, Harrow, United Kingdom

EC905 Pharmacokinetic Profile Study

Phase 1

Completed

Conditions: Healthy
Phase 1
Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: EC905
Drug: Tamsulosin HCl
Drug: Solifenacin Succinate

First Posted Date: 2015-12-18

Last Posted Date: 2015-12-18

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 46

Registration Number: NCT02634489

Locations: 🇳🇱
Site NL1, Zuidlaren, Drente, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy